{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-010245","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.458582+00:00","generated_at":"2026-05-25T09:49:27.452890+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ocugen FY2024 net loss $0.20; advances three gene therapy programs toward BLA filings","bullets":["Q4 net loss $0.05/share; full-year net loss $0.20/share vs $0.26 in 2023.","Cash $58.8M as of Dec 31, 2024; runway into Q1 2026; $65M financing secured in H2 2024.","OCU400 Phase 3 RP enrollment on track for H1 2025; BLA/MAA target mid-2026.","OCU410ST Stargardt Phase 2/3 pivotal trial FDA-aligned; BLA target 2027.","OCU410 GA completed Phase 2 dosing; no serious adverse events; BLA target 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-010245","json":"https://secwatch.observer/filing/0001628280-25-010245.json","markdown":"https://secwatch.observer/filing/0001628280-25-010245.md","text":"https://secwatch.observer/filing/0001628280-25-010245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/0001628280-25-010245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/ocgn-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T09:49:27.452890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}